HS-10376
/ Jiangsu Hansoh Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 28, 2022
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=380 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • HER-2
1 to 1
Of
1
Go to page
1